Pfizer Inc. (PFE)
3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May
Though there are countless strategies to grow your wealth on Wall Street, few have proved as successful over the long run as buying and holding high-quality dividend stocks.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks Fox (FOXA), Universal Technical Institute (UTI), Pfizer (PFE), Tenet Healthcare (THC) and Newmont (NEM) are likely to beat on the bottom line in their upcoming releases.
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs.
Pfizer's Q1 Update May Mark A Bottom In The Stock
Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again.
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away
Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US.
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
Pfizer Inc. (PFE) Q1 2025 Earnings Call Transcript
Pfizer Inc. (NYSE:PFE ) Q1 2025 Results Conference Call April 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investment Relations Officer and Senior Vice President Dr. Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Chris Boshoff - Chief Scientific Officer Aamir Malik - Chief U.S. Commercial Officer and Executive Vice President Alexandre de Germay - Executive Vice President & Chief International Commercial Officer Andrew Baum - Chief Strategy & Innovation Officer and Executive Vice President Conference Call Participants Vamil Divan - Guggenheim Evan Seigerman - BMO Capital Markets Tim Anderson - Bank of America Steve Scala - Cowen Umer Raffat - Evercore ISI Chris Schott - JPMorgan Geoff Meacham - Citi Trung Huynh - UBS Kerry Holford - Berenberg Akash Tewari - Jefferies Terence Flynn - Morgan Stanley Dave Reisinger - Leerink Mohit Bansal - Wells Fargo Courtney Breen - Bernstein Assad Haider - Goldman Sachs Operator Good day, everyone, and welcome to Pfizer's First Quarter 2025 Earnings Conference Call. Today's call is being recorded.
Pfizer's 7% Yield Makes It Look Like a Junk Bond—But Better
The big decline in Pfizer's share price may have a silver lining.
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
Compared to Estimates, Pfizer (PFE) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer delivers mixed results for Q1, expands cost-cutting program
Pfizer Inc (NYSE:PFE, ETR:PFE) reported mixed results for the first quarter, including an earnings beat but revenue below expectations. Revenue fell 8% from the year-ago quarter to $13.7 billion, below estimates of $14 billion.
